insulin secretagogues - sulfonylureas

Description Results NMA

metformin and gliclazide (n=-9)

vs.

metformin and rosiglitazone (n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration: 24 weeks

gliclazide plus metformin (n=-9)

vs.

nateglinide plus metformin (n=-9)

double-blind

Sample size: -9/-9

Primary endpoint:

FU duration: 52 weeks

gliclazide 80 mg o.d. (titrated up to 320 mg (n=313)

vs.

pioglitazone 15 mg o.d. (titrated up to 45 mg (n=317)

double-blind

Sample size: 313/317

Primary endpoint:

FU duration: 52 weeks

glimepiride monotherapy (n=-9)

vs.

metformin monotherapy (n=-9)

double-blind

Sample size: -9/-9

Primary endpoint:

FU duration: 20 weeks

glimepiride (4 mg once daily). (n=-9)

vs.

placebo (n=-9)

double-blind

Sample size: -9/-9

Primary endpoint:

FU duration: 26 weeks

CV death 1.00 [0.38; 2.62]

All-cause mortality 1.00 [0.38; 2.62]

Stroke 1.00 [0.38; 2.62]

Myocardial infarction 1.00 [0.38; 2.62]

glimepiride, 1, 4, or 8 mg once daily (n=304)

vs.

placebo (n=0)

double-blind

Parallel groups

Sample size: 304/0

Primary endpoint:

FU duration: 14 weeks

glimepiride at individually determined optimal dose (1-8 mg of glimepiride) for 10+12 weeks (n=123)

vs.

placebo (n=126)

double-blind

Parallel groups

Sample size: 123/126

Primary endpoint:

FU duration:

glimepiride 8 mg q.d., 4 mg b.i.d., 16 mg q.d., or 8 mg b.i.d (n=416)

vs.

placebo (n=0)

double-blind

Parallel groups

Sample size: 416/0

Primary endpoint:

FU duration: 14 weeks

glimepiride with titration to 2 mg and 4 mg for FPG levels >120 mg/dL (n=-9)

vs.

placebo (n=-9)

double-blind

Parallel groups

Sample size: -9/-9

Primary endpoint: change in HbA(1c)

FU duration: 14 weeks

metformin and glimepiride (n=-9)

vs.

metformin (n=-9)

metformin, glimepiride or metformin and glimepiride

double-blind

Sample size: -9/-9

Primary endpoint:

FU duration:

glimepiride 0.25mg od, 0.5mg od (n=62)

vs.

placebo (n=31)

Sample size: 62/31

Primary endpoint:

FU duration:

glimepiride 1-8mg od (n=122)

vs.

placebo (n=125)

Sample size: 122/125

Primary endpoint:

FU duration:

Glimepiride (16 mg/day) plus insulin (n=72)

vs.

insulin plus placebo (n=73)

Sample size: 72/73

Primary endpoint:

FU duration:

glimepiride 1-4mg od (n=96)

vs.

gliclazide 80-320 mg/day (od or bid) (n=107)

Sample size: 96/107

Primary endpoint:

FU duration:

glimepiride 1 mg daily (n=524)

vs.

2.5 mg glibenclamide (n=520)

double-blind

Parallel groups

Sample size: 524/520

Primary endpoint: not unique

FU duration:

glimepiride 1-16mg od (n=289)

vs.

non-micronized glyburide 1.25-20mg od (n=288)

double-blind

Parallel groups

Sample size: 289/288

Primary endpoint:

FU duration:

glimepiride (n=172)

vs.

gliclazide or glibenclamide (n=0)

open

Parallel groups

Sample size: 172/0

Primary endpoint:

FU duration: 6 months

glimepiride 1-8mg od (n=427)

vs.

glibenclamide 1.75-14 mg/day (od or bid) (n=425)

Sample size: 427/425

Primary endpoint:

FU duration:

glimepiride 1-16 mg/day (od or bid) (n=444)

vs.

glipizide 2.5-40 mg/day (od or bid) (n=208)

Sample size: 444/208

Primary endpoint:

FU duration:

glimepirid e6mg od (n=50)

vs.

glimepiride 3mg bid (n=48)

Cross over

Sample size: 50/48

Primary endpoint:

FU duration:

glipizide (n=-9)

vs.

sitagliptin (n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration: 52 weeks

2.5 mg glipizide GITS (n=61)

vs.

placebo (n=61)

double-blind

Sample size: 61/61

Primary endpoint:

FU duration: 16 weeks

glipizide, 2.5 or 5 mg/day (n=139)

vs.

glyburide, 1.25 or 2.5 mg/day (n=0)

open

Parallel groups

Sample size: 139/0

Primary endpoint:

FU duration: 4 months

glipizide (n=-9)

vs.

glyburide (n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

glipizide (n=-9)

vs.

glyburide (n=-9)

double-blind

Parallel groups

Sample size: -9/-9

Primary endpoint:

FU duration: 15 months

once-daily doses of 5, 20, 40, or 60 mg glipizide GITS (n=-9)

vs.

placebo (n=-9)

double-blind

Parallel groups

Sample size: -9/-9

Primary endpoint:

FU duration: 4+8 weeks

5 to 20 mg of glipizide gastrointestinal therapeutic system (GITS) (n=377)

vs.

placebo (n=192)

Parallel groups

Sample size: 377/192

Primary endpoint:

FU duration: 12 weeks

glipizide/metformin 5/500 mg tablets (n=-9)

vs.

metformin 500-mg (n=-9)

glipizide 30-mg, metformin 500-mg, or glipizide/metformin 5/500 mg

open

Cross over

Sample size: -9/-9

Primary endpoint:

FU duration:

metformin-glibenclamide 500/2.5 mg tablets (initial daily dose 1000/5 mg) (n=-9)

vs.

metformin 500 mg plus rosiglitazone 4 mg (initial daily dose 1000-2000 mg + 4 mg, depending on previous treatment) (n=-9)

double-blind

Sample size: -9/-9

Primary endpoint:

FU duration: 24 weeks

glyburide 2.5 mg (n=-9)

vs.

placebo (n=-9)

double-blind

Parallel groups

Sample size: -9/-9

Primary endpoint:

FU duration:

glibenclamide (2.5 mg X 3/d) (n=-9)

vs.

placebo (n=-9)

double-blind

Factorial plan

Sample size: -9/-9

Primary endpoint:

FU duration:

metformin + glibenclamide (n=-9)

vs.

metformin (n=-9)

metformin, glibenclamide or the combination of both

Parallel groups

Sample size: -9/-9

Primary endpoint:

FU duration: 6 months

metformin and glyburide (n=-9)

vs.

metformin (n=-9)

metformin and glyburide vs. metformin vs. glyburide

double-blind

Sample size: -9/-9

Primary endpoint:

FU duration: 29 weeks

low-dose glyburide plus metformin (n=-9)

vs.

high-dose glyburide alone (n=-9)

Cross over

Sample size: -9/-9

Primary endpoint:

FU duration:

metformin-glibenclamide 500 mg/2.5 mg or metformin-glibenclamide 500 mg/5 mg, titrated with the intention to achieve fasting plasma glucose (FPG) < or = 7 mmol/l (n=-9)

vs.

metformin 500 mg, (n=-9)

metformin 500 mg, glibenclamide 5 mg, metformin-glibenclamide 500 mg/2.5 mg or metformin-glibenclamide 500 mg/5 mg

double-blind

Parallel groups

Sample size: -9/-9

Primary endpoint:

FU duration: 16 weeks

glyburide/metformin 2.5 mg/500 mg (n = 160); or glyburide/metformin 5 mg/500 mg (n = 162) (n=-9)

vs.

metformin 500 mg (n=-9)

glyburide 10 mg b.i.d. (n = 164); metformin 500 mg (n = 153); glyburide/metformin 2.5 mg/500 mg (n = 160); or glyburide/metformin 5 mg/500 mg

double-blind

Parallel groups

Sample size: -9/-9

Primary endpoint:

FU duration: 16 weeks

metformin 400 to 2,400 mg/d + glibenclamide 2.5 to 15 mg/d (n=-9)

vs.

metformin (500 to 3,000 mg/d), (n=-9)

metformin (500 to 3,000 mg/d), glibenclamide (5 to 15 mg/d), or their combination (metformin 400 to 2,400 mg/d + glibenclamide 2.5 to 15 mg/d

double-blind

Cross over

Sample size: -9/-9

Primary endpoint:

FU duration: 6 months

glyburide/metformin (n=-9)

vs.

metformin (n=-9)

glyburide/metformin tablets vs. metformin or glyburide monotherapy

Parallel groups

Sample size: -9/-9

Primary endpoint:

FU duration: